Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ANLBIO

Explore full profile

Pioneering non-GMP AAV solutions for rare genetic diseases with a focus on research and development

Suwon, South KoreaFounded 2019
Valuation $50–100M Last recorded · 2022
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for ANLBIO and the history behind them.

About ANLBIO

ANL Bio operates in the biotechnology sector, specializing in the development of non-GMP grade adeno-associated virus (AAV) solutions. The company targets rare genetic diseases, with a pipeline that includes candidates for conditions such as Lafora disease, ALS, and Fronto Temporal Dementia. ANL Bio collaborates with partners like Modalis Therapeutics to advance its research and development efforts. The business model revolves around providing cell-specific AAV research engines and non-GMP grade contract manufacturing organization (CMO) services. Revenue is generated through partnerships, research collaborations, and the commercialization of its pipeline candidates. The company serves clients in the pharmaceutical and biotech industries, focusing on those seeking specialized AAV solutions for genetic disorders.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Suwon, South Korea
Open positions
None listed
Dealroom signal
16.3/100
Business model
Manufacturing
Client focus
b2b
Links
Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Feb 2022 $10M $42M BNK Venture Investment · Hyundai Technology Investments · Posco Capital · Friend Investment Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

ANLBIO website traffic

Latest recorded traffic for ANLBIO is 3K monthly website visits, up 581.8% over the last three months.

Latest monthly visits3K 3-month web change+581.8%
Monthly website visitsMay 2023–Feb 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • BNK Venture Investment
  • Hyundai Technology Investments
  • Posco Capital
  • Friend Investment Partners

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea · Suwon HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ANLBIO on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ANLBIO’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.